Key result
Adding cardiac biomarkers to clinical models boosts LVH detection to ~0.81 AUC in CKD.
Why the study?
Asymptomatic LVH is often missed in routine CKD screening, and it remained unclear whether a cardiorenal biomarker-enhanced model improves detection of prevalent LVH in non-dialysis CKD.
Does a biomarker-enhanced model incorporating UACR, NT-proBNP, and sST2 improve detection of prevalent left ventricular hypertrophy compared to a clinical model alone in non-dialysis patients with chronic kidney disease?
Cross-Sectional (n=647)
Does a biomarker-enhanced model incorporating UACR, NT-proBNP, and sST2 improve detection of prevalent left ventricular hypertrophy compared to a clinical model alone in non-dialysis patients with chronic kidney disease?
Answers are grounded in this paper and cite their sources.
Incorporating cardiorenal biomarkers (UACR, NT-proBNP, and sST2) into a clinical prediction model improves the detection of prevalent left ventricular hypertrophy in non-dialysis CKD patients, potentially helping to prioritize echocardiography referrals.
BACKGROUND: Left ventricular hypertrophy (LVH) acts as a key factor for determinant of adverse cardiovascular outcomes in patients with chronic kidney disease (CKD). Echocardiography is the standard method for LVH assessment. Yet asymptomatic LVH patients are often overlooked or missed in routine screening. Whether a biomarker-enhanced model improves detection of prevalent LVH in non-dialysis CKD remains unclear. METHODS: This cross-sectional study included 647 non-dialysis patients with CKD. We developed a clinical model based on female, age, body mass index, systolic blood pressure, hypertension, cardiovascular disease, estimated glomerular filtration rate, and serum phosphorus. Cardiorenal biomarkers, including urine albumin-to-creatinine ratio (UACR), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and soluble suppression of tumorigenicity 2 (sST2), were then added to assess their incremental value. Model performance was evaluated using discrimination, calibration, bootstrap internal validation, and decision curve analysis. RESULTS: LVH was present in 131 patients (20.2%). In multivariable analysis, female, hypertension, serum phosphorus, UACR, and sST2 were independently associated with LVH. NT‑proBNP was associated with LVH in univariable but not multivariable analysis. The clinical model had an AUC of 0.789. Adding three biomarkers improved the AUC to 0.812 (95% CI, 0.769-0.856), with lower Brier score and AIC. Bootstrap internal validation showed an optimism-corrected AUC of 0.790 and Brier score of 0.129. Decision curve analysis suggested higher net benefit for the biomarker-enhanced model across most threshold probabilities. CONCLUSIONS: A biomarker-enhanced model incorporating UACR, NT-proBNP, and sST2, have potential clinical applications to help prioritize echocardiography referrals for asymptomatic CKD patients who may have prevalent LVH.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2026) conducted a cross-sectional in Non-dialysis chronic kidney disease (CKD) with prevalent left ventricular hypertrophy (LVH) (n=647). Cardiorenal biomarker-enhanced model (incorporating UACR, NT-proBNP, and sST2) vs. Clinical model alone (female sex, age, BMI, systolic blood pressure, hypertension, cardiovascular disease, eGFR, and serum phosphorus) was evaluated on Detection of prevalent left ventricular hypertrophy (LVH) (AUC 0.812, 95% CI 0.769-0.856). Adding UACR, NT-proBNP, and sST2 to a clinical model improved detection of prevalent LVH in non-dialysis CKD patients from an AUC of 0.789 to 0.812.
Synapse has enriched 10 related papers. Consider them for comparative context: